• SIGN IN
  • GET HELP
  •  

    Home Study Details


    Program Type

    Home Study Webcast

    Credits

    1 Contact Hour(s)

    Release Date

    Wednesday, June 14, 2017

    Offline Date

    Saturday, December 14, 2019

    ACPE Expiration Date

    Saturday, December 14, 2019

    Target Audience

    Pharmacist, Pharmacy Technician, Nurse

    Cost

    $4.00

    • Overview

      A consensus document detailing the management of dyslipidemia with regard to the use of non-statin therapy was recently released in July 2016. New evidence regarding the use of non-statin therapy (i.e., results from IMPROVE IT and HPS2-THRIVE) has been released and new drugs approved (i.e., the PCSK9 inhibitors) since publication of the 2013 ACC/AHA lipid guideline. This has lead to gaps in the guideline regarding clinical decision making surrounding the use of non-statin drugs. It is imperative to disseminate recommendations of this new decision pathway to healthcare practitioners, so that they can provide evidence-based, patient-centered care as members of an interdisciplinary team.

      Rating

         4.50  out of 5

      Handouts

      • Slide Document :   16159H01_4pp.pdf
      • Slide Document :   16159H01_2pp.pdf

      Financial Support By

      PharmCon
    • Pharmacist

      Review recommendations from the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of ASCVD Risk
      Recognize the role of non-statin pharmacotherapy in dyslipidemia management
      Describe the background of dyslipidemia and atherosclerotic cardiovascular disease (ASCVD)
      Identify patient-specific pharmacotherapy plans to optimize outcomes for patients with dyslipidemia

      Pharmacy Technician

      Recognize the role of non-statin pharmacotherapy in dyslipidemia management
      Describe the background of dyslipidemia and atherosclerotic cardiovascular disease (ASCVD)
      Review recommendations from the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of ASCVD Risk

      Nurse

      Describe the background of dyslipidemia and atherosclerotic cardiovascular disease (ASCVD)
      Recognize the role of non-statin pharmacotherapy in dyslipidemia management
      Review recommendations from the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of ASCVD Risk
      Identify patient-specific pharmacotherapy plans to optimize outcomes for patients with dyslipidemia
    • Activity Type

      Knowledge

      CE Broker

      20-557437

      Universal Activity Number

      Pharmacist 0798-0000-16-159-H01-P
      Pharmacy Technician 0798-0000-16-159-H01-T
      Nurse 0798-0000-16-159-H01-P

      ACPE PharmCon is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

      PharmCon is an approved course provider for continuing education for nurses by the Florida Board of Nursing. PharmCon is also recognized by the California Board of Nursing as a provider of nursing programs.

      In order to obtain a Statement of Credit, participants must score no less than a 70% on the activity's test and complete a program evaluation.


    HARDWARE REQUIREMENTS
    Standard Windows/Mac System
    iPad or iPhone
    Minimum screen resolution: 1024x768
    Speakers or headphones
     


    SOFTWARE REQUIREMENTS
    Microsoft Edge
    Internet Explorer 8.0 or higher
    Google Chrome
    Safari
    Firefox 3.0.3 or higher


    NETWORK REQUIREMENTS
    Broadband Internet Connection:
    T1, Hi-speed DSL or Cable
    4G cellular connection
     
     

    This continuing education activity is held as copyright by PharmCon, Inc. Through this notice, PharmCon, Inc. grants permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).